Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of two intravenous methylprednisolone regimens for active moderate-to-severe Graves' ophthalmopathy
ChiCTR-IPR-15006848Phase 4Completed
- Sponsor
- Tongji Hospital
- Start
- Mar 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methylprednisolone in Graves' ophthalmopathy (TED) (2 arms), sponsored by Tongji Hospital. Primary endpoints: Ophthalmologic examination and Maximum T2 relaxation times and maximum areas. Started Mar 2011; status: completed.
02
Drugs
methylprednisolone
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on ChiCTR-IPR-15006848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006848.